|
Patient characteristics
|
Patients (n = 33)
|
|---|
| |
No.
|
%
|
|---|
|
Age
|
59 years
|
|
Median (range)
|
(35–68)
|
|
PS (ECOG)
| | |
|
Median (range)
|
0 (0–1)
|
|
Menopausal status
| | |
|
Pre
|
6
|
18.2
|
|
Post
|
27
|
81.8
|
|
Stage
| | |
|
Locally advanced
|
7
|
21.2
|
|
Metastatic:
| | |
|
1 site
|
9*
|
27.3
|
|
≥ 1 site
|
17
|
51.5
|
|
Site
| | |
|
Breast
|
12
|
36.4
|
|
Bone
|
20
|
60.6
|
|
Liver
|
12*
|
36.4
|
|
Lung
|
8
|
24.2
|
|
Lymph nodes
|
4
|
12.1
|
|
Receptor status
| | |
|
ER+
|
22
|
66.7
|
|
ER-
|
8
|
24.2
|
|
Unknown
|
3
|
9.1
|
|
Prior therapy
| | |
|
None
|
16
|
48.5
|
|
Adjuvant hormonal therapy
|
4
|
12.1
|
|
Adjuvant chemotherapy
|
7
|
21.2
|
|
Chemo- and hormone adjuvant therapy
|
4
|
12.1
|
|
Hormone therapy for advanced disease
|
6
|
18.2
|
- *One instrumentally detected hepatic lesion was histologically diagnosed a posteriori as an angioma
